Biogen price target raised to $157 from $150 at HSBC
HSBC analyst Morten Herholdt raised the firm's price target on Biogen to $157 from $150 and keeps a Reduce rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperformance potential for the second half of the year, noting that the Therapeutics sp